Private jets owned by six of the largest U.S. drugmakers have touched down in Washington-area airports 127 times this year, ...

Medicare beneficiaries will see major pricing shifts as federal negotiations reshape how costly prescription drugs are paid ...

Pharmacy leaders say 2026 is shaping up to be a year defined by financial volatility, regulatory pressure and workforce strain — all intensified by upcoming federal drug pricing reforms. Across ...

Hospital groups raise issues with 340B rebate pilot program citing cash flow, administrative costs, and unclear rebate denials risks.

Congress continually struggles to find bipartisan reforms that improve affordability and increase the quality of care; ...

The IRA requires health plans serving the Part D market to cover all negotiated drugs, and it has been predicted that CMS ...

Americans face rising health care costs. Learn what's driving prices and how insurers aim to make care more affordable.

A new Tufts study found that Medicare price negotiations on biologics with imminent biosimilars could lead to near-term savings, but greater savings are likely from biosimilar competition.

Competing policy efforts to lower drug prices could muddy the waters of drug pricing and leave patients unable to afford ...

I’ve spent most of my career in public service, including time in the United States and Michigan House of Representatives, ...

Medicare’s second round of drug price negotiations will cut prices on 15 expensive treatments by up to 85% starting in 2027, ...

With Medicare Open Enrollment ending next week, the Centers for Medicare & Medicaid Services (CMS) has announced that last ...